Month: July 2020

PETERBOROUGH, CA, July 21, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Rainmaker Worldwide (OTC:RAKR) announces the appointment of Steve Grasso to the Company’s Advisory Board, effective immediately.Grasso is the Director of Institutional Sales at Stuart Frankel & Co. Inc. and an On Air Market Analyst on CNBC. His achievements in trade has made him a recognized and respected voice across financial markets.Grasso began his career in the early ‘90s on The New York Stock Exchange (NYSE) floor, joining Stuart Frankel & Co. in 1999 as an institutional sales trader. For over 20 years, Grasso has been working with the largest mutual funds, pension funds, insurance companies and hedge funds, providing real-time trading advice and services. Clients are kept informed on changes to policy and regulation as a result of Grasso’s...

50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trialSubject to regulatory approval, a randomized, double-blinded, placebo-controlled, multinational Phase III part of the trial will be initiatedPrimary endpoint of the planned Phase III part to be 28-day all-cause mortality       JENA, Germany, July 21, 2020 (GLOBE NEWSWIRE) — InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that the Company has decided to continue development with IFX-1 in severe COVID-19 induced pneumonia.  The Company plans to initiate a double-blinded, randomized, placebo-controlled Phase III trial that will be adequately powered for...

This year’s annual symposium coincides with the expected launch of Avicanna Inc’s (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) RHO Phyto™ advanced medical cannabis products, manufactured by MediPharm Labs.In the wake of COVID-19, a virtual format will be used that allows for a broader reach to global patients and the medical community.The symposium will present the evolution of medical cannabis including the Avicanna-led advancements, in collaboration with MediPharm Labs for R&D for novel cannabinoid delivery forms and formulations in addition to enhanced access for patients by Medical Cannabis by Shoppers.Leading experts in R&D and clinical development will discuss the potential therapeutic benefits of medical cannabis to address the importance of working with healthcare practitioners for safe and effective dosing.BARRIE,...

BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases and Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced today that they have entered into a strategic collaboration and license agreement to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies.Under the agreement, MyoKardia will access Fulcrum’s unique, proprietary target discovery engine to identify therapeutics that control the expression of genes that are known to be underlying drivers of genetic cardiomyopathies....

STAMFORD, Conn., July 21, 2020 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (Nasdaq: EGLE) will report its financial results for the second quarter ended June 30, 2020, after the close of stock market trading on Thursday, August 6, 2020. Members of Eagle Bulk’s senior management team will host a teleconference and webcast at 8:00 a.m. ET on Friday, August 7, 2020 to discuss the results.To participate in the teleconference, investors and analysts are invited to call +1 844-282-4411 in the U.S., or +1 512-900-2336 outside of the U.S., and reference participant code 8968944. A simultaneous webcast of the call, including a slide presentation for interested investors and others, may be accessed by visiting http://www.eagleships.com.A replay will be available following the call from 11:00 AM ET on August 7, 2020 until 11:00 AM ET on August...

In the long-term follow-up study of Zolgensma® and real-world experience, it has been reported that some patients previously treated with gene therapy have been treated with SPINRAZA1,2,3The RESPOND study aims to evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to ZolgensmaBiogen continues to advance research in spinal muscular atrophy to address the needs of the community and provide additional data to inform treatment decisionsCAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced it plans to initiate a global Phase 4 clinical study, RESPOND, to examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children with spinal muscular atrophy (SMA) who still have unmet clinical needs following treatment with gene therapy...

BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases and Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced today that they have entered into a strategic collaboration and license agreement to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies.Under the agreement, MyoKardia will access Fulcrum’s unique, proprietary target discovery engine to identify therapeutics that control the expression of genes that are known to be underlying drivers of genetic cardiomyopathies....

ROCHESTER, Mich., July 21, 2020 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, has appointed Greg Wasson, former president and CEO of Walgreen Boots Alliance, to its board of directors.“Consumer awareness of digital health services, and especially the need for better affordability and adherence, has never been greater,” said OptimizeRx CEO and director, William Febbo. “Our platform delivers for the life sciences industry unprecedented access to physicians and patients at the point-of-care. Staying connected with the patient as they enter a physical or virtual pharmacy now presents another important area of opportunity to deliver value to our stakeholders. In light of this, Greg’s experience in building Walgreens as a Fortune 50 company with...

HOUSTON, July 21, 2020 (GLOBE NEWSWIRE) — Penn Virginia Corporation (“Penn Virginia” or the “Company”) (NASDAQ:PVAC) today announced an operational update and timing of its second-quarter 2020 earnings release and conference call.Operational and Financial UpdateEstimated production for the second quarter of 2020 of between 18,500 – 18,900 barrels of oil per day and between 24,100 – 24,600 barrels of oil equivalent per day;Realized oil price for the second quarter of 2020 of approximately $23.97 per barrel and $50.37 per barrel including hedge settlements;Increased oil hedge positions (see appendix);Completed three drilled uncompleted (“DUC”) wells in June 2020;Estimated capital expenditures for the second quarter of 2020 of between $10.5 – $12.5 million;Reduced accounts payable by approximately $45 million in the second quarter...

EAST GREENVILLE, Pa., July 21, 2020 (GLOBE NEWSWIRE) — Knoll, Inc. (NYSE: KNL) today announced the closing of the previously announced purchase of $164.0 million in convertible preferred stock by an independently managed subsidiary of Investindustrial VII L.P.As previously announced, transaction terms follow:$164.0 million of convertible, perpetual preferred stock, which will be convertible into shares of Knoll, Inc. common stock at an initial conversion price of $16.75 per share. The preferred stock carries a 4.50% dividend, which will be payable at Knoll’s option in cash or in-kind for the first 2 years and payable in cash thereafter.Knoll expects to use the net proceeds from the transaction for general corporate purposes, including to reduce outstanding borrowings under its credit facility.About KnollKnoll, Inc. is a constellation...